Founded in 2004, ERYTECH Pharma develops innovative cancer therapies that work by starving tumours. Its first product, which is in phase III development, provides a therapeutic solution to frail patients with acute leukaemia.
ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.
The company has a production unit located in Lyons with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
Clinical trials on track and two new studies started Shareholder base further internationalized Solid cash balance Lyon (France), September 2nd, 2014– ERYTECH (Euronext Paris: FR0011471135 – ERYP),the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and …
ERYTECH Pharma announces that an independent Data and Safety Monitoring Board (DSMB) completed its second safety assessment of the company’s Phase IIb study in Acute Myeloid Leukemia (AML) and unanimously recommended continuation of the trial without modification.
ERYTECH Pharma announces the enrollment of the first patient in its Phase II study with ERY-ASP in second line treatment of patients affected by pancreatic cancer.
ERYTECH Pharma announces the enrollment of the first patient in its Phase I/II study with ERY-ASP in Acute Lymphoblastic Leukemia in the United States of America.
FINANCE – ERYTECH Pharma takes part in CF&B Large & Midcap Event which takes place on October 2 & 3, 2014 in Paris, France.
FINANCE – ERYTECH Pharma attends SG Société Générale Healthcare & Biotechnology Conference on September 24, 2014 in Paris, France.
SCIENTIFIC CONGRESS – ERYTECH Pharma takes part in World CDx which takes place from September 23 to 25 2014 in Boston, MA, USA.
ERYTECH Pharma participates in BioPharm America 2014 from September 22 to 24 2014 in Boston, MA, USA.